Bevacizumab in glioblastoma multiforme

References

• Wen PY, Kesari S. Malignant gliomas in adults. N. Engl. J. Med.359(5), 492–507 (2008).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol.10(5), 459–466 (2009).
   PubMed Web of Science ®Google Scholar
• Bauchet L, Mathieu-Daude H, Fabbro-Peray P et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol. doi:10.1093/neuonc/noq030 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Fuentes-Raspall R, Vilardell L, Perez-Bueno F et al. Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994–2005. J. Neurooncol.101(1), 117–123 (2011).
   PubMedGoogle Scholar
• Scoccianti S, Magrini SM, Ricardi U et al. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology). Neurosurgery67(2), 446–458 (2010).
   PubMedGoogle Scholar
• Koshy M, Vilano JL, Dolecek TA et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J. Clin. Oncol.29(Suppl.), 2013 (2011).
   Google Scholar
• Lwin Z, MacFadden D, Al-Zahrani A et al. A population-based study of glioblastoma multiforme (GBM) in the new stupp paradigm: have we improved outcome? J. Clin. Oncol.29(Suppl.), 2012 (2011) (Abstract).
   Google Scholar
• Preusser M, Woehrer A, Zielonke N et al. Real-life survival in unselected adult glioblastoma patients: A population-based study. J. Clin. Oncol.29(Suppl.), 2014 (2011) (Abstract).
   Google Scholar
• Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol.7(12), 1152–1160 (2008).
   PubMed Web of Science ®Google Scholar
• Lu JF, Bruno R, Eppler S, Novotnv W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother. Pharmacol.62(5), 779–786 (2008).
   PubMed Web of Science ®Google Scholar
• Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol.7(369), (2005) (Abstract).
   Google Scholar
• Taillibert S, Hoang-Xuan K, Barrie M et al. Bevacizumab (B) with irinotecan (I) in recurrent glioblastoma (Gbm): a national retrospective cohort of the ANOCEF (Association des Neuro-Oncologues D’Expression Francaise) Group. Neuro Oncol.12, 52–53 (2010) (Abstract).
   Google Scholar
• Francesconi AB, Dupre S, Matos M et al. Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J. Clin. Neurosci.17(8), 970–974 (2010).
   PubMed Web of Science ®Google Scholar
• Sehebjam S, Ang C, Guiot M et al. Efficacy, safety and pattern of relapse of bevacizumab versus chemotherapy for recurrent glioblastoma multiforme: a McGill University study. Ann. Oncol.21(Suppl. 8), 1059P (2010) (Abstract).
   Google Scholar
• Chamberlain MC, Johnston SK. Salvage therapy with single-agent bevacizumab for recurrent glioblastoma. J. Neurooncol.96(2), 259–269 (2010).
   PubMed Web of Science ®Google Scholar
• Hofer S, Elandt K, Greil R et al. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol.50(5), 630–635 (2011).
   PubMed Web of Science ®Google Scholar
• Nghiemphu PL, Liu W, Lee Y et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology72(14), 1217–1222 (2009).
   PubMed Web of Science ®Google Scholar
• Poulsen HS, Grunnet K, Sorensen M et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol.48(1), 52–58 (2009).
   PubMed Web of Science ®Google Scholar
• Zuniga RM, Torcuator R, Jain R et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol.91(3), 329–336 (2009).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Johnston SK. Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab. J. Neurooncol.102(3), 427–432 (2011).
   PubMedGoogle Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol.25(30), 4722–4729 (2007).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Vredenburgh JJ et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a Phase II study. Br. J. Cancer101(12), 1986–1994 (2009).
   PubMed Web of Science ®Google Scholar
• Soffietti R, Trevisan E, Ruda R et al. Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: final results of a multicenter study of AINO (Italian Association of Neuro-oncology). J. Clin. Oncol.29(Suppl.), 2027 (2011) (Abstract).
   PubMedGoogle Scholar
• Trevisan E, Ruda R, Picco E et al. Bevacizumab and fotemustine as salvage therapy in recurrent glioblastoma: a Phase II multicenter Italian study. Neuro Oncol.12(iii), P117 (2010) (Abstract).
   Google Scholar
• Kobyakov G, Absalyamova O, Amanov R. Bevacizumab in combination with irinotecan or temozolomide in recurrent glioblastoma: efficacy and safety results from a pilot study. Neuro Oncol.12, 54 (2010) (Abstract).
   Google Scholar
• Keyrouz VR, Elias EF, Chahine GY, Comair YG, Dimassi H, Kamar FG. Updated results of a Phase II trial of bevacizumab and irinotecan in relapsed high grade glioma. Neuro Oncol.12(iii), P108 (2010) (Abstract).
   Google Scholar
• Verhoeff JJC, Lavini C, van Linde ME et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann. Oncol.21(8), 1723–1727 (2010).
   PubMedGoogle Scholar
• Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol.27(5), 740–745 (2009).
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Grimm S, Chamberlain MC et al. A Phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer116(22), 5297–5305 (2010).
   PubMed Web of Science ®Google Scholar
• Desjardins A, Vredenburgh JJ, Reardon DA et al. Long-term survival from the initial trial of bevacizumab and irinotecan. J. Clin. Oncol.28(15s), 2045 (2010) (Abstract).
   Google Scholar
• Geludkova OG, Borodina ID, Melikian AG et al. Results of treatment pediatric recurrent high grade glioma with combination of bevacizumab and irinotecan. Neuro Oncol.12(iii), P131 (2010) (Abstract).
   Google Scholar
• Gururangan S, Chi SN, Poussaint TY et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a pediatric brain tumor consortium study. J. Clin. Oncol.28(18), 3069–3075 (2010).
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol.27(28), 4733–4740 (2009).
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Vredenburgh JJ, Day B, Das A, Friedland HS. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. J. Clin. Oncol.28(15s), 2008 (2010) (Abstract).
   PubMedGoogle Scholar
• Prados M, Cloughesy T, Samant M et al. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol.13(1), 143–151 (2011).
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Cloughesy T, Samant M et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist15(12), 1329–1334 (2010).
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Wang MH, Aldape K et al. Rtog 0625: a randomized Phase II trial of bevacizumab with either irinotecan (Cpt) or dose-dense temozolomide (Tmz) in recurrent glioblastoma (Gbm). Neuro Oncol.12, 39 (2010) (Abstract).
   Google Scholar
• van den Bent M, Taal W, Sleijfer S et al. Toxicity of combined bevacizumab-lomustine treatment in patients with recurrent glioblastoma (Gbm): report from a randomized Phase II study. Neuro Oncol.12, 42 (2010) (Abstract).
   Google Scholar
• Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. Ann. Neurol.68(4), S61–S62 (2010) (Abstract).
   Google Scholar
• Norden AD, Bartolomeo J, Tanaka S et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J. Neurooncol. doi:10.1007/s11060-011-0642-1 (2011) (Epub ahead of print).
   Google Scholar
• Clark AJ, Butowski NA, Chang SM et al. Impact of bevacizumab chemotherapy on craniotomy wound healing. J. Neurosurg.114(6), 1609–1616 (2011).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Raizer J. Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology75(3), 289–290 (2010).
   PubMedGoogle Scholar
• Sherman JH, Aregawi DG, Lai A et al. Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology73(22), 1924–1926 (2009).
   PubMedGoogle Scholar
• Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol.28(17), 2817–2823 (2010).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Mulholland P, Neyns B, et al. A Phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients. Ann. Oncol.21(Suppl. 8), LBA7 (2010) (Abstract).
   Google Scholar
• Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol.28(7), 1168–1174 (2010).
   PubMed Web of Science ®Google Scholar
• Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium Phase I and II clinical trials. J. Clin. Oncol.25(18), 2601–2606 (2007).
   PubMed Web of Science ®Google Scholar
• Pace A, Conti L, Russillo M et al. Bevacizumab-based therapy recurrent malignant glioma: correlation between serum VEGF and response to treatment. Neuro Oncol.12, 33–34 (2010).
   Google Scholar
• Nangia CS, Wang D, Scarpace L, Schultz L, Khanshour A, Mikkelsen T. The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme (GBM). J. Clin. Oncol.29(Suppl.), 2021 (2011) (Abstract).
   Web of Science ®Google Scholar
• Wu J, Gilbert MR, de Groot JF, Yung WA, Puduvalli VK. Diffusion restriction as a predictor of response in recurrent glioblastoma patients receiving bevacizumab. J. Clin. Oncol.28(15s), 2024 (2010) (Abstract).
   PubMedGoogle Scholar
• Gupta A, Young RJ, Karimi S, et al. Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma. AJNR Am. J. Neuroradiol.32(7), 1301–1306 (2011).
   PubMedGoogle Scholar
• Gerstner ER, Frosch MP, Batchelor TT. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J. Clin. Oncol.28(6), e91–e93 (2010).
   PubMedGoogle Scholar
• Chen W, Delaloye S, Silverman DHS et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol.25, 4714–4721 (2007).
   PubMed Web of Science ®Google Scholar
• Quant EC, Norden AD, Drappatz J et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol.11(5), 550–555 (2009).
   PubMed Web of Science ®Google Scholar
• Iwamoto FM, Abrey LE, Beal K et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology73(15), 1200–1206 (2009).
   PubMed Web of Science ®Google Scholar
• Zuniga RM, Torcuator R, Jain R et al. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J. Neurooncol.99(2), 237–242 (2010).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Peters K et al. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J. Neurooncol.103(2), 371–379 (2011).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Vredenburgh JJ, Desjardins A et al. Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials. J. Clin. Oncol.29(Suppl.), 2030 (2011) (Abstract).
   Google Scholar
• Wick A, Dörner N, Schäfer N et al. Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann. Neurol.69(3), 586–592 (2011).
   PubMed Web of Science ®Google Scholar
• Cuneo KC, Cabrera AR, Sampson JH et al. Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma. J. Clin. Oncol.29(Suppl.), 2082 (2011) (Abstract).
   Google Scholar
• Gutin PH, Iwamoto FM, Beal K et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys.75(1), 156–163 (2009).
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Desjardins A, Vredenburgh JJ et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol.12(12), 1300–1310 (2010).
   PubMed Web of Science ®Google Scholar
• Hasselbalch B, Lassen U, Hansen S et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a Phase II trial. Neuro Oncol.12(5), 508–516 (2010).
   PubMed Web of Science ®Google Scholar
• Moustakas A, Iwamoto FM, Kreisl TN et al. Phase II trial of enzastaurin (Enz) with bevacizumab (Bv) in adults with recurrent glioblastoma (Gem). Neuro Oncol.12, 37 (2010) (Abstract).
   PubMedGoogle Scholar
• Gaziel TB, Soerensen M, Hasselbalch B, Poulsen HS, Lassen U. Phase II study of bevacizumab and temsirolimus in patients with progressive glioblastoma multiforme after prior bevacizumab treatment. Neuro Oncol.12, 40 (2010).
   Google Scholar
• Bota DA, Eroglu Z, Reardon DA et al. Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma. J. Clin. Oncol.29(Suppl.), 2056 (2011) (Abstract).
   Google Scholar
• Galanis E, Jaeckle KA, Anderson SK et al. NCCTG Phase II trial of bevacizumab in combination with sorafenib in recurrent GBM. J. Clin. Oncol.28(15s), 2018 (2010).
   Google Scholar
• Drappatz J, Raizer JJ, Schiff D et al. A Phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG). J. Clin. Oncol.29(Suppl.), 2050 (2011) (Abstract).
   Google Scholar
• Lou E, Reardon DA, Peters K et al. Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. J. Clin. Oncol.29(Suppl.), 2055 (2011) (Abstract).
   Google Scholar
• Chauffert B, Feuvet L, Bonnetain F et al. Randomized multicenter Phase II trial of irinotecan and bevacizumab as neoadjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma: interim results of the TEMAVIR study from the ANOCEF group. J. Clin. Oncol.29(Suppl.), 2029 (2011) (Abstract).
   Google Scholar
• Hofland KF, Poulsen HS, Sorensen MP et al. First-line therapy with bevacizumab and irinotecan versus bevacizumab and temozolomide and delayed concomitant radiotherapy in newly diagnosed primary glioblastoma multiforme: early results from a randomized Phase II study. Neuro Oncol.11(5), 620 (2009) (Abstract).
   Google Scholar
• Vredenburgh JJ, Desjardins A, Reardon DA et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide and irinotecan for newly diagnosed glioblastoma. Clin.Cancer Res.69(3), 586–592 (2011).
   Google Scholar
• Lai A, Tran A, Nghiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol.29(2), 142–148 (2011).
   PubMed Web of Science ®Google Scholar
• Omuro AM, Beal K, Karimi S et al. Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM). J. Clin. Oncol.29(Suppl.), 2028 (2011) (Abstract).
   Web of Science ®Google Scholar
• Chinot OL, de La Motte Rouge T, Moore N et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv. Ther.28(4), 334–340 (2011).
   PubMed Web of Science ®Google Scholar
• Shih KC, Spikel DR, Burris HA III, Brown RH, Shepard GC, Hainsworth JD. Phase II trial of radiation therapy/temozolomide/bevacizumab followed by bevacizumab/everolimus in the first-line treatment of glioblastoma multiforme (GBM). J. Clin. Oncol.28(15s), 2075 (2010) (Abstract).
   Google Scholar
• Cohen MH, Shen YL, Keegan P, Pazdur R. FDA Drug Approval Summary: bevacizumab (Avastin®) as treatment of recurrent glioblastoma multiforme. Oncologist14(11), 1131–1138 (2009).
   PubMed Web of Science ®Google Scholar
• Balana C, Etxaniz O, Buges C, Martinez A. Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error? Clin. Transl. Oncol.13(3), 209–210 (2011).
   PubMed Web of Science ®Google Scholar